Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis.

ABSTRACT:

Importance

There is a need for better understanding of the comparative safety of systemic medications used in the treatment of psoriasis.

Objective

To compare the risk of serious infection associated with biologic and nonbiologic systemic medications in patients with psoriasis.

Design, setting, and participants

An observational cohort study was conducted using medical and outpatient pharmacy claims from 2 large US health insurance claims databases from January 1, 2003, through September 30, 2015. We included patients with a diagnosis of psoriasis who were new users of systemic medications for psoriasis.

Exposures

Prescription claims for acitretin, adalimumab, apremilast, etanercept, infliximab, methotrexate, or ustekinumab.

Main outcomes and measures

The

SUBMITTER: Dommasch ED 

PROVIDER: S-EPMC6512303 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature